Posts

Vitruvias shuts down after thyroid-drug recall as Baxter expands injectable recalls

on

Brepocitinib Shows Sustained Skin Benefits in Phase 3 Dermatomyositis Trial

on

Forrester Healthcare: AI-enabled care must meet rising patient expectations

on

Sword Health Plans to Acquire Headspace in Reported $200M–$300M Cash Deal

on

ZS at Dreamforce: 2026 presence announced, session details still limited

on

Aurora’s Personalized CRISPR Ambition Hits Regulatory and Competitive Roadblocks

on

Spyre abandons standalone RA ambitions for SPY072 after modest Phase 2 results

on

FDA approves Revolution Medicines’ Rasonque, marking a major advance in KRAS/RAS-targeted pancreatic-cancer treatment

on

Insilico Medicine Reports Profitable First Half of 2026 as AI Drug-Discovery Deals Accelerate

on

Haisco licenses immunology asset to new U.S. biotech Sentivera in deal worth up to $1.5 billion

on

SK Biopharmaceuticals Signs Up-to-$795 Million Biohaven Deal for Epilepsy Drug

on

FDA reportedly considers new technology and drugs deputy commissioner posts

on

FDA reportedly approves Revolution Medicines’ Rasonque for advanced pancreatic cancer

on